|
Source |
Non-harmful / below threshold / severity degree 0 | Mild / severity degree 1 | Moderate / severity degree 2 | Severe / severity degree 3 |
| Directive 2010/63/EU, Annex VIII |
Induction of tumours, or spontaneous tumours, that cause no detectable clinical adverse effects (e.g. small, subcutaneous, non-invasive nodules). | Models of induction of tumours, or spontaneous tumours, that are expected to cause moderate pain or distress or moderate interference with normal behaviour. | Models with induction of tumours, or with spontaneous tumours, that are expected to cause progressive lethal disease associated with long lasting moderate pain, distress or suffering. For example tumours causing cachexia, invasive bone tumours, tumours resulting in metastatic spread, and tumours that are allowed to ulcerate. | |
| Federal Food Safety and Veterinary Office FSVO (2018) |
Models with subcutaneous endogenous tumours if the experiment is terminated before the tumour (owing to its size and location) leads to an impairment of general condition and no cytostatics are administered. Examples:Passage of primary tumours and tumour cell lines. Breeding and maintenance of transgenic or knock-out models of cancer. |
Models with induction or transplantation of tumours or with spontaneous tumour development, which are treated with experimental therapies. Experiments are terminated before cancer cachexia or other progressive lethal disease or clinically manifest functional (incl. endocrine) or behavioural disturbances (due to the size, location or other properties of the tumour, or to metastasis) occur in the animal. Weight loss max. 15%. Examples:Tests of experimental therapies in transplantation models of cancer and in transgenic or knock-out models of cancer. |
Models with induction or transplantation of tumours, or with spontaneous tumour development, which cause cancer cachexia or other progressive lethal disease, or which are not discontinued before clinically manifest functional (incl. endocrine) disturbances (due to the size, location or other properties of the tumour, or to metastasis) occur in the animal. Weight loss max. 20%. Examples:Experiments with dose escalation. Tumour therapy models with survival endpoints. |
|
| Working Group of Berlin Animal Welfare Officers (2010) |
Models with subcutaneously localised tumours, where no functional disorders are caused in the animal, and no cytostatic drug is administered. |
Models not leading to tumour cachexia or other progressively lethal diseases, or being cancelled before functional disorders occur in the animal. |
Models leading to tumour cachexia or other progressively lethal diseases, or not being cancelled before functional disorders occur in the animal. |
Did you find what you were looking for?
Yes, I found it! No, I did not!Thanks for your feedback! Please note that we cannot reply to you unless you send us an email.
What are you looking for?
We value your feedback so we can improve the information on the page. Please add your email address if you would like a reply. Thank you in advance for your help.!
Please contact us by email if you have any questions.